Navigation Links
Right first time: Pioneering new methods of drug manufacture
Date:11/11/2009

Engineers at the University of Leeds have developed a simple technology which can be used in existing chemical reactors to ensure "right first time" drug crystal formation.

Ensuring drug crystals are formed correctly is crucial to their efficacy and the efficiency of pharmaceutical manufacturers' operations. Using self-assembled monolayers, the team has been able to show that crystals form into their desired product form with the correct shape and particle structure, without the usual problems of polymorphism which results in huge losses to the pharmaceutical sector each year.

"If you imagine the way that oil sits on top of water, that's similar to how the monolayer works," says Professor Kevin Roberts of University's Faculty of Engineering. "We've shown that we can produce a well-defined crystal structure using a self-assembled monolayer bound onto a metal substrate within a regular reactor. This is exciting stuff, because it's a relatively simple system, but could make a huge difference in the efficiency of drug manufacture."

One of the first stages of the crystallisation process is called nucleation. During nucleation, particles are introduced into a reactor to encourage the formation of crystals. However, the way in which this is currently carried out is difficult to control and can often lead to the wrong shape, size or structure of drug crystal, something which affects the usefulness and efficacy of the compound.

The new system proven to work by the Leeds team, working alongside Ana Kwokal from Croatian pharmaceutical company PLIVA, has shown that introducing a self-assembled monolayer a layer of self-organising molecules that is attractive to the substance being crystallised into a reactor enables consistent crystal formation.

Professor Roberts says: "Because this is a really simple solution to ensuring consistent crystallisation, it has huge potential commercially. Our next steps are to make sure it's just as efficient on an industrial scale."

This work draws on previous research and experimental systems developed through the Chemicals Behaving Badly II initiative, an Engineering and Physical Sciences Research Council (EPSRC) programme which includes universities and industrial partners.


'/>"/>

Contact: Clare Elsley
Clare@campuspr.co.uk
44-113-258-9880
University of Leeds
Source:Eurekalert

Related medicine news :

1. Physicians for Human Rights Offers Training in Crime Scene Documentation
2. Bright Horizons Named One of Boston Globe 100s Top Places to Work
3. Good Sleepers More Likely to Eat Right
4. Mom was right: Nice guys dont always finish last
5. Rights Tracker Completes Fundraising
6. Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin
7. Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
8. AHIP Is Right, and May Be Low
9. Researchers discover mechanism that helps humans see in bright and low light
10. Go Healthy Secures Nationwide Distributorship Rights to Patented Drinking Water
11. Right Now Sale/Leaseback May Be the Only Option to Obtain Cash and a Healthier Balance Sheet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2016)... ... December 11, 2016 , ... Traditional cell phone chargers serve a very ... case for chargers used for tablets, portable laptops, and other mobile devices with rechargeable ... charges its respective device. An inventor from Floral Park, N.Y., has developed the patent-pending ...
(Date:12/11/2016)... ... , ... It’s hard for an inventor from Hanover, Pa., to spend time ... eyes and general discomfort associated with allergic reactions, he decided to develop an easy ... the patent-pending CLEAN AIR NOSE FILTER, an accessory that provides relief of allergic reactions ...
(Date:12/11/2016)... FL (PRWEB) , ... December 11, 2016 , ... ... to the online market. Skinerals Organic Skin Science has introduced 16 new products ... explains Michael Schindele, creator of Skinerals, "And we wanted to supply more products ...
(Date:12/11/2016)... , ... December 11, 2016 , ... ... has announced its 2017 program schedule, now available online. This year’s conference event ... research concerning eating disorders. The dynamic Symposium will take place March 22 - ...
(Date:12/10/2016)... ... December 09, 2016 , ... ... survival rates have increased greatly in recent years. This can be attributed to ... that progress hasn’t been equally distributed. In response, Mediaplanet’s latest, cross-platform edition of ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)...  Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... filed a lawsuit for patent infringement.  The lawsuit, filed ... of Delaware , alleges that Nevro ... stimulation leads, batteries, and telemetry units. ...
(Date:12/9/2016)... 2016 MSD, a nationally recognized supplier of ... alternate site health care facilities, announced today that it ... ("First Choice"), a privately held national distributor of medical ... home health segments. We would like to welcome First ... compelling transaction will deliver significant and immediate value to ...
(Date:12/9/2016)... , December 9, 2016 ... Subcutaneous ICD, Single-Chamber ICD, Dual-Chamber ICD, Cardiac Resynchronization ... Defibrillators, Wearable Cardioverter Defibrillators The ... at a CAGR of 5.3% from 2016-2020 and ... expected to grow at a CAGR of 5.2% ...
Breaking Medicine Technology: